Estimación del poder de mercado de la empresa farmacéutica Pfizer en el mercado privado de medicamentos para el tratamiento de la enfermedad de artritis reumatoide en el Perú
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsAguilar Lizana, Mayra Danitza
Espejo Galindo, Andrea Valeri
Navarro Vargas, Jacqueline Solange
MetadataShow full item record
CitationLizana, A., Danitza, M., Galindo, E., Valeri, A., Vargas, N., & Solange, J. (2017). Estimación del poder de mercado de la empresa farmacéutica Pfizer en el mercado privado de medicamentos para el tratamiento de la enfermedad de artritis reumatoide en el Perú. Universidad Peruana de Ciencias Aplicadas (UPC). Retrieved from http://hdl.handle.net/10757/621477%0A%0A
AbstractThe pharmaceutical industry represents a growing number of markets. Globally, they are characterized by an oligopolistic organization, which is at the base of product dependence, where competition at the global level is controlled by approximately 20 companies. In this industry, laboratories have a large percentage of their budget for research and development, in order to achieve a competitive advantage in their products. As a result, they permanently secure monopoly revenues through the patent system and marketing chains (Correa, 1992) The present research focuses on estimating and analyzing the market power of the pharmaceutical company Pfizer, in the rheumatologic diseases in the private sector in Peru. To do this, we calculate economically an estimate of the Lerner index. The study is based for statistical purposes on historical sales data for the drug Xeljanz, a drug that is used to aid in the treatment of moderate to severe rheumatoid arthritis and currently only sold in Peru. With the data provided by Pfizer, it will be done for the estimation of marginal historical costs, to define the Lerner index, in this way to measure the level of power of the market monopoly that Pfizer has in this market. At the same time, using the net sales and the deflated price, a simple statistical regression will be made, so that we can establish the demand curve and through it, the relationship between the amount demanded and the price of Xeljanz. In this way the econometric model will allow to calculate an estimate of price elasticity based on demand, which indirectly allows to analyze the reaction of the market to a variation of the price. Thus we hope to obtain as a result the market power exercised by Pfizer in the marketing of this drug within the local pharmaceutical industry as far as rheumatic diseases are concerned. The relevance of our study is based on the number of people who present this disease in our country. Since the prevalence rate of rheumatoid arthritis in Peru is 0.5%. Therefore, of the 31, 200 000 Peruvian citizens, approximately 156,000 suffer from this disease, according to the National Institute of Statistics and computing (INEI, 2015). We consider it important to determine the market power that the Pfizer company has over the production and marketing of the drug Xeljanz, since the central objective of this work provides, marginally but with relevant results, the state of knowledge, for analytical purposes, of the Pharmaceutical industry in Peru.